Copyright
©2013 Baishideng Publishing Group Co.
World J Cardiol. May 26, 2013; 5(5): 132-140
Published online May 26, 2013. doi: 10.4330/wjc.v5.i5.132
Published online May 26, 2013. doi: 10.4330/wjc.v5.i5.132
Table 1 Antropometric, clinical and biochemical characteristics of study participants (mean ± SD) n (%)
Characteristics | |
Age, yr | 65.1 ± 9.8 |
BMI, kg/m2 | 26.2 ± 4.7 |
SBP, mm/Hg | 138 ± 19 |
DBP, mm/Hg | 83 ± 9 |
Cholesterol, mg/dL | 234 ± 49 |
TG, mg/dL | 125 ± 70 |
HDL cholesterol, mg/dL | 66 ± 11 |
LDL cholesterol, mg/dL | 143 ± 47 |
EH | 120 (61) |
LVH | 53 (27) |
CHD | 45 (23) |
Type 2 diabetes | 23 (12) |
Myocardial infarction | 8 (4) |
Family history of EH | 75 (38) |
Family history of myocardial infarction | 51 (26) |
Table 2 Antropometric, clinical and biochemical characteristics of study participants from the 1st and 2nd quartiles of distribution of 15059G>A heteroplasmy level n (%)
Characteristics | 15059G>A heteroplasmy level1 | P value | |
Quartile 1 (n = 49) | Quartile 4 (n = 48) | ||
Age, yr | 60.1 ± 7.1 | 66.2 ± 9.9 | 0.001 |
BMI, kg/m2 | 26.4 ± 4.5 | 27.1 ± 5.1 | 0.41 |
SBP, mm/Hg | 132 ± 18 | 143 ± 22 | 0.022 |
DBP, mm/Hg | 83 ± 12 | 84 ± 12 | 0.50 |
Cholesterol, mg/dL | 228 ± 42 | 243 ± 43 | 0.10 |
TG, mg/dL | 112 ± 57 | 141 ± 61 | 0.021 |
HDL cholesterol, mg/dL | 66 ± 14 | 68 ± 19 | 0.69 |
LDL cholesterol, mg/dL | 140 ± 40 | 147 ± 44 | 0.44 |
EH | 22 (45) | 30 (63) | 0.17 |
LVH | 13 (27) | 13 (27) | 0.97 |
Table 3 Antropometric, clinical and biochemical characteristics of coronary heart disease patients from the 1st and 2nd quartiles of distribution of 15059G>A heteroplasmy level n (%)
Characteristics | 15059G>A heteroplasmy level1 | P value | |
Quartile 1 (n = 11) | Quartile 4 (n = 10) | ||
Age, yr | 63.2 ± 7.0 | 72.9 ± 8.7 | 0.011 |
BMI, kg/m2 | 27.2 ± 6.2 | 26.1 ± 5.9 | 0.69 |
SBP, mmHg | 129 ± 22 | 153 ± 22 | 0.03 |
DBP, mmHg | 80 ± 12 | 85 ± 13 | 0.32 |
Cholesterol, mg/dL | 224 ± 54 | 236 ± 49 | 0.59 |
TG, mg/dL | 130 ± 77 | 121 ± 56 | 0.78 |
HDL cholesterol, mg/dL | 62 ± 15 | 69 ± 15 | 0.39 |
LDL cholesterol, mg/dL | 136 ± 47 | 143 ± 42 | 0.69 |
EH | 7 (64) | 7 (70) | 0.86 |
LVH | 4 (36) | 4 (40) | 0.68 |
Table 4 Antropometric, clinical and biochemical characteristics of CHD-free study participants from the 1st and 2nd quartiles of distribution of 15059G>A heteroplasmy level n (%)
Characteristics | 15059G>A heteroplasmy level1 | P value | |
Quartile 1 (n = 38) | Quartile 4 (n = 37) | ||
Age, yr | 59.4 ± 7.2 | 64.7 ± 8.8 | 0.005 |
BMI, kg/m2 | 26.0 ± 4.0 | 27.4 ± 5.3 | 0.2 |
SBP, mmHg | 132 ± 14 | 141 ± 21 | 0.17 |
DBP, mmHg | 84 ± 11 | 84 ± 10 | 0.99 |
Cholesterol, mg/dL | 231 ± 41 | 246 ± 47 | 0.14 |
TG, mg/dL | 106 ± 46 | 147 ± 61 | 0.003 |
HDL cholesterol, mg/dL | 67 ± 14 | 67 ± 18 | 0.99 |
LDL cholesterol, mg/dL | 143 ± 37 | 150 ± 42 | 0.44 |
EH | 15 (39) | 23 (62) | 0.19 |
LVH | 10 (26) | 10 (27) | 0.98 |
Table 5 Comparison of antropometric, clinical and biochemical characteristics of study participants from “low heteroplasmy” and “high heteroplasmy” groups n (%)
Characteristics | 15059G>A heteroplasmy level1 | P value | |
Low (n = 99) | High (n = 97) | ||
Age, yr | 60.2 ± 8.4 | 68.6 ± 8.4 | < 0.001 |
BMI, kg/m2 | 26.3 ± 4.1 | 27.0 ± 5.0 | 0.52 |
SBP, mmHg | 133 ± 16 | 142 ± 18 | 0.024 |
DBP, mmHg | 82 ± 11 | 84 ± 11 | 0.39 |
Cholesterol, mg/dL | 232 ± 48 | 241 ± 48 | 0.27 |
TG, mg/dL | 118 ± 56 | 135 ± 62 | 0.065 |
HDL cholesterol, mg/dL | 67 ± 14 | 66 ± 15 | 0.92 |
LDL cholesterol, mg/dL | 141 ± 42 | 148 ± 44 | 0.49 |
EH | 51 (52) | 69 (71) | 0.033 |
LVH | 20 (20) | 33 (34) | 0.1 |
Table 6 Association between the 15059G>A heteroplasmy level and essential hypertension prevalence
15059G>A heteroplasmy level | No hypertension, n | Hypertension, n | Odds ratio (95%CI) | P value |
Low (< 31%) | 51 | 51 | ||
High (> 31%) | 25 | 69 | 2.76 (1.45-5.27) | 0.019 |
Total | 76 | 120 |
- Citation: Sobenin IA, Chistiakov DA, Sazonova MA, Ivanova MM, Bobryshev YV, Orekhov AN, Postnov AY. Association of the level of heteroplasmy of the 15059G>A mutation in the MT-CYB mitochondrial gene with essential hypertension. World J Cardiol 2013; 5(5): 132-140
- URL: https://www.wjgnet.com/1949-8462/full/v5/i5/132.htm
- DOI: https://dx.doi.org/10.4330/wjc.v5.i5.132